Xanthate based radical cascade toward multicomponent formation of pyrrolopyrimidines
Laurent El Kaim, Laurence Grimaud, Patil Pravin

To cite this version:
Laurent El Kaim, Laurence Grimaud, Patil Pravin. Xanthate based radical cascade toward multicomponent formation of pyrrolopyrimidines. Molecules, MDPI, 2011, 16 (11), pp.9261-9273. 10.3390/molecules16119261. hal-00951237

HAL Id: hal-00951237
https://hal-polytechnique.archives-ouvertes.fr/hal-00951237
Submitted on 7 Apr 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Xanthate Based Radical Cascade Toward Multicomponent Formation of Pyrrolopyrimidines

Laurent El Kaïm *, Laurence Grimaud * and Patil Pravin

Laboratoire DCSO ENSTA-Polytechnique-CNRS, UMR 7652, Ecole Nationale Supérieure de Techniques Avancées, 32 Bd Victor, 75739 Paris Cedex 15, France

* Authors to whom correspondence should be addressed; E-Mails: laurent.elkaim@ensta.fr (L.E.K.); grimaud@dcso.polytechnique.fr (L.G.); Tel.: +33145525537; Fax: +33145528322.

Received: 28 September 2011; in revised form: 23 October 2011 / Accepted: 28 October 2011 / Published: 4 November 2011

Abstract: A short sequential synthesis of pyrrolidino- pyridines and pyrimidines illustrates the potential of combining Ugi-Smiles couplings with radical tin-free processes.

Keywords: Ugi-Smiles coupling; xanthates; multicomponent reactions; radical processes; isocyanides

1. Introduction

Among multi-component reactions (MCRs), the Ugi reaction has a privileged position due to its broad synthetic significance [1,2]. Its four points of diversity combined with possible further transformations of the resulting adducts have became very popular in heterocyclic synthesis. Indeed, the Ugi reaction has been associated with a wide range of post-condensation reactions in order to form even more complex scaffolds, including cycloadditions [3-9], metal-catalyzed processes [10-15] and cyclocondensations [16-21]. Among this very impressive bibliography, the combination of Ugi or Passerini reactions with radical chemistry has been scarcely documented [22-27]. Among the various radical systems explored in our group, we have mostly studied the potential of xanthate radical transfer resulting in various cyclizations of Ugi xanthate adducts bearing suitable alkene [22], alkyne [25] or aryl [26] moieties. In all these examples, α-chloroacetic acid was used as the acidic partner to introduce the xanthate moiety via a nucleophilic substitution. However, these intramolecular post-condensations did not exploit the full potential of the xanthate radical transfer. Indeed, compared
to tin hydride chemistry, the reversible nature of the addition of radicals onto the thiocarbonyl group is associated with high yielding intermolecular couplings between xanthates and alkenes [28,29]. Herein, we propose to explore this feature and to further increase the molecular diversity of the Ugi step through a xanthate triggered addition/cyclization cascade to form new heterocyclic systems (Scheme 1).

**Scheme 1.** Synthetic strategy towards pyrrolidino fused systems.

**2. Results and Discussion**

Developing the radical chemistry of xanthates, the Zard group has reported various synthetic approaches towards fused cyclic systems such as indanes, indolines or azaindolines [30-35]. These syntheses feature an intermolecular addition of a xanthate on an alkene followed by an intramolecular trapping with a suitably positioned aryl group. As part of our ongoing interest in Ugi-type reactions, we naturally imagined to synthesize the radical acceptor through a Ugi-Smiles coupling. Indeed, we recently developed the use of electron-deficient phenols as acid surrogates in Ugi reactions to form \( N \)-arylamino carboxamides [36,37]. The use of a partner substituted with an alkene, such as allylamine, in this reaction would afford in one step an interesting substrate to test the tandem radical process (Scheme 1). Concerning the phenol, most reported Ugi-Smiles couplings involve a nitro group to perform the Smiles rearrangement. As nitroaryl derivatives are often associated with inhibition of radical chain processes, we prefer the use of hydroxy heterocycles (pyridines, pyrimidines) which also led to efficient multicomponent couplings [38]. \( N \)-allylaminopyridines and \( N \)-allylaminopyrimidines are known to react with xanthate under radical conditions, however the scope of these reactions seems to be limited by the nucleophilic behavior of the cyclic nitrogen atom. Indeed all reported radical tandem were performed on 2- or 5-halosubstituted heterocycles (chloro and fluoro) in order to lower the reactivity at the nitrogen center (Scheme 2) [31-35].
Scheme 2. Selected examples from Zard’s group [31,33].

2.1. Four-Component Coupling Towards Radical Substrates

Various Ugi-Smiles adducts were thus prepared starting with allylamine as the amine partner. The latter was coupled with different hydroxy-pyridines and pyrimidines. The MCR coupling was performed under classical conditions using methanol as solvent. The starting radical substrates were obtained in modest to good yields.

Table 1. Preparation of the radical substrates.

<table>
<thead>
<tr>
<th>Entry</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
<th>Y</th>
<th>Z</th>
<th>Product (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Et</td>
<td>Cy</td>
<td>Me</td>
<td>Me</td>
<td>N</td>
<td>N</td>
<td>1a (38%)</td>
</tr>
<tr>
<td>2</td>
<td>i-Bu</td>
<td>Cy</td>
<td>H</td>
<td>H</td>
<td>N</td>
<td>CH</td>
<td>1b (69%)</td>
</tr>
<tr>
<td>3</td>
<td>i-Bu</td>
<td>t-Bu</td>
<td>H</td>
<td>H</td>
<td>N</td>
<td>CH</td>
<td>1c (43%)</td>
</tr>
<tr>
<td>4</td>
<td>Et</td>
<td>Cy</td>
<td>Ph</td>
<td>Me</td>
<td>N</td>
<td>N</td>
<td>1d (61%)</td>
</tr>
<tr>
<td>5</td>
<td>H</td>
<td>p-MeBn</td>
<td>Ph</td>
<td>Me</td>
<td>N</td>
<td>N</td>
<td>1e (60%)</td>
</tr>
<tr>
<td>6</td>
<td>Et</td>
<td>Cy</td>
<td>H</td>
<td>H</td>
<td>CNO₂</td>
<td>N</td>
<td>1f (41%)</td>
</tr>
<tr>
<td>7</td>
<td>i-pr</td>
<td>p-ClBn</td>
<td>Me</td>
<td>Me</td>
<td>N</td>
<td>N</td>
<td>1g (68%)</td>
</tr>
</tbody>
</table>

2.2. Radical Cascade

In previous studies on xanthate additions on N-allylamino-pyridines and pyrimidines, a first 1,2-addition product on the alkene could be obtained and isolated under heating with substoichiometric amounts of a radical initiator such as dilauroyl peroxide (DLP) in refluxing 1,2-dichloroethane (DCE) or ethyl acetate. Then the intermediate adducts could cyclize under treatment with further DLP or di-tert-butyl peroxide (more than 1 equivalent) at higher temperature allowing cleaner reactions (Scheme 3).
Even if the yields are expected to be lower, we preferred to perform the cascade under a single set of experimental conditions in order to keep the multicomponent sequence as short as possible. When adduct 1a was refluxed in DCE (0.2 M) with DLP added in 15 mol% portions every twenty minutes, we could isolate the desired cyclized pyrrolidine 2a as a 9:1 mixture of diastereomers [39] in 48% isolated yield, after overall addition of 1.5 equivalent of DLP (Scheme 3).

**Scheme 3. Radical reaction conditions.**

This sequence is initiated by decomposition of the xanthate into the electrophilic radical I, which is then trapped by the alkene moiety to give intermediate II. The latter is an electron-rich radical that can react with the starting xanthate to form intermediate IV. The latter being slightly less reactive than the starting xanthate towards radicals issued from DLP, accumulates in the medium and reacts when further amount of DLP is added without much 1 left to enter in the chain process. After addition of the radical onto the aryl ring, the intermediate species III further aromatize through interaction with the DLP (Scheme 4).

**Scheme 4. Plausible mechanism.**

To evaluate the scope of this cyclization, the reaction was performed with the Ugi-Smiles adducts formerly prepared and the results are displayed in Table 2.
Table 2. Radical additions-Cyclizations.

<table>
<thead>
<tr>
<th>Entry</th>
<th>Ugi-Smiles adduct</th>
<th>Xanthate</th>
<th>Cyclized product</th>
<th>Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><img src="1b" alt="Image" /></td>
<td><img src="2b" alt="Image" /></td>
<td><img src="2b" alt="Image" /></td>
<td>24</td>
</tr>
<tr>
<td>2</td>
<td><img src="1c" alt="Image" /></td>
<td><img src="2c" alt="Image" /></td>
<td><img src="2c" alt="Image" /></td>
<td>27</td>
</tr>
<tr>
<td>3</td>
<td><img src="1d" alt="Image" /></td>
<td><img src="2d" alt="Image" /></td>
<td><img src="2d" alt="Image" /></td>
<td>55</td>
</tr>
<tr>
<td>4</td>
<td><img src="1d" alt="Image" /></td>
<td><img src="2e" alt="Image" /></td>
<td><img src="2e" alt="Image" /></td>
<td>44</td>
</tr>
<tr>
<td>5</td>
<td><img src="1e" alt="Image" /></td>
<td><img src="2f" alt="Image" /></td>
<td><img src="2f" alt="Image" /></td>
<td>27</td>
</tr>
<tr>
<td>6</td>
<td><img src="1f" alt="Image" /></td>
<td><img src="2g" alt="Image" /></td>
<td><img src="2g" alt="Image" /></td>
<td>48</td>
</tr>
<tr>
<td>7</td>
<td><img src="1a" alt="Image" /></td>
<td><img src="2h" alt="Image" /></td>
<td><img src="2h" alt="Image" /></td>
<td>34</td>
</tr>
<tr>
<td>8</td>
<td><img src="1g" alt="Image" /></td>
<td><img src="2i" alt="Image" /></td>
<td><img src="2i" alt="Image" /></td>
<td>43</td>
</tr>
</tbody>
</table>
Pyridines and pyrimidines without any halogen substituent at the 2 or 5 position can act as radical trapping agents in this sequence. In the study disclosed by Zard, initial attempts with 2-aminopyridine or 2-amino-5-methylpyridine as starting materials led to successful 1,2-addition product with the xanthate, but no indolizine could be formed in the following cyclization step [31]. Chloro or fluoro substituents are expected to lower the electron density in the aromatic ring leading to easier addition of the nucleophilic intermediate radical species, and this may explain the moderate yields observed. In our case, the reaction turns out to be poorly efficient with 4-aminopyridines, with yields not exceeding 30% (Table 2, Entries 1–2), a nitro group at the 5-position of the 2-aminopyridine ring activates the cyclization as a higher 48% isolated yield could be obtained (Table 2, Entry 6). Pyrimidines, in agreement with their higher electrophilicity, are better partners, giving yields over 50% with simple alkyl or aryl substituents on the heterocyclic core (Table 2, Entry 3).

3. Experimental

3.1. General

$^{1}$H-NMR spectra were recorded on a 400 MHz spectrometer (Bruker Avance 400), using CDCl$_3$ solvent as reference and/or internal deuterium lock. $^{13}$C-NMR spectra were recorded on a 100.6 MHz spectrometer (Bruker Avance 400). Two-dimensional NMR spectroscopy [$^{1}$H–$^{1}$H COSY spectra, $^{1}$H–$^{13}$C COSY spectra (HSQC) and long-range $^{1}$H–$^{13}$C COSY spectra (HMBC)], were carried out to determine the correlation between $^{1}$H and $^{13}$C. The chemical shifts for all NMR spectra are expressed in parts per million to high frequency of TMS reference. Coupling constants ($J$) are quoted in Hz and are recorded to the nearest 0.1 Hz. The IR spectra were obtained using ATR accessories on a Bruker Tensor 27 instrument. High-resolution (HR) mass spectra were recorded on a Hewlett-Packard HP 5989B spectrometer. TLC was carried out using precoated plates of silica gel 60F254 (SDS-Carlo-Erba).

3.2. Ugi-Smiles Coupling Procedure

To a 1 M solution of hydroxyheteroaromatic compound in methanol were added successively 1.0 equivalent of amine, 1.0 equivalent of aldehyde and 1.0 equivalent of isocyanide. The resulting mixture was stirred at 65 °C for 18–36 h. The solvent was removed afterwards under reduced pressure to afford the Ugi-Smiles product after purification by flash chromatography on silica gel.

3.3. DLP-Cyclisation Reaction Procedure

A solution of Ugi-Smiles adduct (1.0 mmol) and xanthate (1.2 mmol) in 1,2-dichloroethane (1.0 M) was refluxed for 5 min under argon before DLP was added (60 g, 0.15 mmol) from the top of the condenser. Portions of DLP (60 mg, 0.15 mmol) were added every 20 min until complete disappearance of Ugi-Smile adduct and the starting xanthate, then the remaining DLP was added every 20 min until complete disappearance of the intermediate (TLC monitoring). Concentration under reduced pressure afforded an oily pale brown residue, which was purified by flash chromatography eluting with petroleum ether/diethyl ether to give the pure product as a mixture of two diastereomers. In all the cases, the spectral data are given for the major diastereomer.
Molecules 2011, 16

2-(N-Allyl-N-(2,6-dimethylpyrimidin-4-yl)amino)-N-cyclohexylbutanamide (1a). Yellow solid, (1.0 g, 38%), mp 124–125 °C; ¹H-NMR: δ (ppm) 6.69 (br s, 1H), 6.11 (s, 1H), 5.86–5.69 (m, 1H), 5.27–5.01 (m, 3H), 4.08 (dd, 1H, J = 4.8, 17.0 Hz), 3.84 (d, 1H, J = 17.0 Hz), 3.75–3.63 (m, 1H), 2.51 (s, 3H), 3.32 (s, 3H), 2.13–2.00 (m, 1H), 1.92–1.81 (m, 1H), 1.78–1.59 (m, 3H), 1.58–1.46 (m, 2H), 1.40–1.22 (m, 2H), 1.20–1.06 (m, 2H), 1.02–0.93 (m, 1H), 0.90 (t, 3H, J = 7.3 Hz); ¹³C-NMR: δ (ppm) 170.1, 166.1, 165.3, 162.6, 133.5, 116.9, 100.3, 58.8, 47.6, 47.3, 32.9, 32.7, 26.1, 25.5, 24.5, 24.4, 24.3, 21.9, 10.9; IR (thin film): 2929, 2855, 2356, 1657, 1583, 1539, 1479, 1448, 1403, 1343, 1273, 1177, 1089 cm⁻¹; HRMS: Calcd. for C₁₉H₃₉N₄O: 330.2420, Found: 330.2425.

2-(N-Allyl-N-(pyridin-4-yl)amino)-N-tert-butyl-4-methylpentanamide (1b). Pale yellow solid, (475 mg, 69%), mp 110–111 °C; ¹H-NMR: δ (ppm) 8.23 (dd, 2H, J = 1.6, 5.2 Hz), 6.59 (dd, 2H, J = 1.6, 5.2 Hz), 5.95–5.80 (m, 2H), 5.29–5.21 (m, 2H), 4.25 (t, 1H, J = 6.9 Hz), 4.00 (dd, 1H, J = 5.2, 17.2 Hz), 3.90 (dd, 1H, J = 5.2, 17.2 Hz), 3.80–3.69 (m, 1H), 2.08–2.00 (m, 1H), 1.86–1.76 (m, 2H), 1.70–1.53 (m, 5H), 1.39–1.25 (m, 2H), 1.15–1.00 (m, 3H), 0.92 (d, 3H, J = 6.7 Hz), 0.90 (d, 3H, J = 6.7 Hz); ¹³C-NMR: δ (ppm) 169.9, 153.0, 150.2, 133.2, 118.1, 108.3, 61.0, 49.7, 48.4, 37.7, 32.9, 25.4, 25.2, 24.7, 22.9, 22.1; IR (thin film): 2930, 2853, 1652, 1596, 1544, 1513, 1450, 1235, 1169 cm⁻¹; HRMS: Calcd. for C₂₀H₃₁N₃O: 329.2467, Found: 329.2467.

2-(N-Allyl-N-(pyridin-4-yl)amino)-N-cyclohexyl-4-methylpentanamide (1c). Pale yellow solid, (360 mg, 43%), mp 111–112 °C; ¹H-NMR: δ (ppm) 8.25 (dd, 2H, J = 1.6, 5.0 Hz), 6.59 (dd, 2H, J = 1.6, 5.0 Hz), 5.90–5.80 (m, 2H), 5.28–5.19 (m, 2H), 4.19 (dd, 1H, J = 5.9, 8.0 Hz), 4.00 (ddt, 1H, J = 1.5, 5.0, 17.2 Hz), 3.81 (ddt, 1H, J = 1.5, 5.0, 17.2 Hz), 3.80–3.69 (m, 1H), 2.08–2.00 (m, 1H), 1.86–1.76 (m, 2H), 1.27 (s, 9H), 0.91 (d, 3H, J = 6.6 Hz), 0.89 (d, 3H, J = 6.6 Hz); ¹³C-NMR: δ (ppm) 170.0, 153.0, 149.8, 133.1, 117.9, 108.3, 61.4, 51.4, 49.6, 37.5, 28.5, 25.0, 22.8, 22.2; IR (thin film): 2964, 2930, 2871, 1676, 1596, 1544, 1513, 1454, 1367, 1266, 1231, 1172 cm⁻¹; HRMS: Calcd. for C₁₉H₂₉N₃O: 303.2311, Found: 303.2309.

2-(N-Allyl-N-(6-methyl-2-phenylpyrimidin-4-yl)amino)-N-cyclohexylbutanamide (1d). White solid, (600 mg, 61%), mp 114–115 °C; ¹H-NMR: δ (ppm) 8.50–8.27 (m, 2H), 7.60–7.38 (m, 3H), 6.60 (br s, 1H), 6.24 (s, 1H), 5.94–5.76 (m, 1H), 5.42–5.03 (m, 3H), 4.11 (d, 1H, J = 17.0 Hz), 3.96 (d, 1H, J = 17.0 Hz), 3.77–3.61 (m, 1H), 2.45 (s, 3H), 2.24–2.08 (m, 1H), 1.89–1.74 (m, 2H), 1.68–1.38 (m, 4H), 1.33–1.13 (m, 2H), 1.04–0.80 (m, 6H); ¹³C-NMR: δ (ppm) 170.2, 166.0, 162.8, 162.6, 138.2, 133.5, 130.2, 128.4, 127.9, 117.1, 101.3, 59.7, 47.7, 32.8, 32.6, 25.3, 24.6, 24.4, 24.3, 21.6, 11.1; IR (thin film): 2929, 2850, 1658, 1591, 1570, 1526, 1474, 1443, 1377, 1260, 1208, 1181, 1024 cm⁻¹; HRMS: Calcd. for C₂₁H₂₉N₄O: 392.2576, Found: 392.2575.

2-(N-Allyl-N-(6-methyl-2-phenylpyrimidin-4-yl)amino)-N-p-tolylmethan-acetamide (1e). White solid, (498 mg, 60%), mp 124–125 °C; ¹H-NMR: δ (ppm) 8.43–8.24 (m, 2H), 7.52–7.35 (m, 3H), 7.02 (d, 2H, J = 8.0 Hz), 6.94 (d, 2H, J = 8.0 Hz), 6.79 (br s, 1H), 6.25 (s, 1H), 5.91–5.80 (m, 1H), 5.31–5.14 (m, 2H), 4.39 (s, 2H), 4.29 (s, 2H), 4.16 (s, 2H), 2.44 (s, 3H), 2.25 (s, 3H); ¹³C-NMR: δ (ppm) 169.5, 166.4, 163.3, 162.1, 137.9, 136.9, 134.7, 131.3, 130.2, 129.2, 128.2, 128.0, 127.3, 117.8, 99.9, 52.2, 51.4, 42.9, 24.5, 21.0; IR (thin film): 2920, 2356, 1653, 1591, 1570, 1531, 1496, 1439, 1408, 1374, 1260, 1230, 1194, 1068, 1024 cm⁻¹; HRMS: Calcd. for C₂₉H₂₈N₄O: 386.2107, Found: 386.2104.
Molecules 2011, 16 9268

2-((N-allyl-N-(5-nitropyridin-2-yl)amino)-N-cyclohexylbutanamide (1f). Yellow solid, (508 mg, 41%), mp 111–112 °C, ¹H-NMR: δ (ppm) 9.04 (d, 1H, J = 2.2 Hz), 8.21 (dd, 1H, J = 2.2, 9.4 Hz), 6.52 (d, 1H, J = 9.4 Hz), 6.18 (br s, 1H), 5.87–5.72 (m, 1H), 5.38–5.11 (m, 3H), 4.23 (dd, 1H, J = 4.8, 17.0 Hz), 4.03 (d, 1H, J = 17.0 Hz), 3.78–3.66 (m, 1H), 2.19–2.03 (m, 1H), 1.96–1.83 (m, 1H), 1.80–1.49 (m, 5H), 1.43–1.22 (m, 2H), 1.21–1.06 (m, 2H), 1.05–0.88 (m, 4H); ¹³C-NMR: δ (ppm) 169.2, 160.7, 145.6, 132.9, 132.7, 126.7, 117.6, 106.7, 60.0, 48.0, 47.9, 32.9, 32.8, 25.4, 24.5, 21.9, 10.8; IR (thin film): 2924, 2850, 1657, 1588, 1570, 1496, 1413, 1325, 1286, 1251, 1111 cm⁻¹; HRMS: Calcd. for C₁₈H₂₆N₄O₅: 346.2005, Found: 346.2016.

N-((4-Chlorobenzyl)-2-(N-allyl-N-(2,6-dimethylpyrimidin-4-yl)amino)-3-methylbutanamide (1g). White solid, (2.1 gm, 68%), mp 97–98 ºC, ¹H-NMR: δ (ppm) 7.23 (d, 2H, J = 8.2 Hz), 7.07 (d, 2H, J = 8.2 Hz), 6.13 (s, 1H), 5.70–5.55 (m, 1H), 5.13 (d, 2H, J = 13.3 Hz), 4.91 (br s, 1H), 4.40–4.25 (m, 2H), 4.10–3.90 (m, 2H), 2.56–2.42 (m, 1H), 2.38 (s, 3H), 2.33 (s, 3H), 1.02 (d, 3H, J = 6.4 Hz), 0.81 (d, 3H, J = 6.4 Hz); ¹³C-NMR: δ (ppm) 170.9, 166.1, 165.4, 162.6, 136.7, 133.1, 133.0, 128.9, 128.7, 117.4, 100.6, 42.6, 26.5, 26.1, 24.1, 19.9, 19.1; IR (thin film): 2968, 1671, 1583, 1535, 1474, 1403, 1339, 1268, 1203, 1085 cm⁻¹; HRMS: Calcd. for C₂₁H₂₇ClN₄O: 386.1873, Found: 386.1868.

Ethyl 3-((7-(1-(cyclohexylcarbamoyl)-6,7-dihydro-2,4-dimethyl-5H-pyrrolo[2,3-d]pyrimidin-5-yl)propanoate (2a). Yellow liquid, (200 mg, 48%), ¹H-NMR: δ (ppm) 6.43 (d, 1H, J = 7.5 Hz), 4.40 (t, 1H, J = 7.7 Hz), 4.06 (q, 2H, J = 6.8 Hz), 3.80–3.63 (m, 2H), 3.40–3.25 (m, 2H), 2.45 (s, 3H), 2.34–2.20 (m, 5H), 2.10–1.95 (m, 2H), 1.90–1.70 (m, 4H), 1.69–1.46 (m, 3H), 1.40–1.05 (m, 8H), 0.88 (t, 3H, J = 7.3 Hz); ¹³C-NMR: δ (ppm) 172.8), 169.1, 166.3, 166.2, 157.2, 116.4, 60.6, 57.9, 50.5, 47.8, 35.0, 32.9, 32.8, 30.4, 28.9, 25.8, 25.4, 24.5, 24.4, 20.8, 20.5, 14.2, 10.7; IR (thin film): 2929, 2855, 2356, 1731, 1657, 1609, 1570, 1517, 1448, 1400, 1312, 1277, 1260, 1168, 1168, 1089, 1028 cm⁻¹; HRMS: Calcd. for C₂₂H₃₆N₄O₅: 416.2787, Found: 416.2767.

Ethyl 3-((1-(cyclohexylcarbamoyl)-3-methylbutyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)propanoate (2b). Pale yellow liquid, (100 mg, 24%), ¹H-NMR: δ (ppm) 8.21 (s, 1H), 8.12 (d, 1H, J = 5.8 Hz), 6.55 (d, 1H, J = 5.8 Hz), 6.04 (br s, 1H), 4.10 (q, 2H, J = 7.1 Hz), 3.93 (t, 1H, J = 6.5 Hz), 3.80–3.60 (m, 3H), 3.00–2.88 (m, 1H), 2.29 (t, 2H, J = 7.0 Hz), 2.02 (dd, 1H, J = 7.0, 13.4 Hz), 1.95–1.78 (m, 4H), 1.74–1.50 (m, 6H), 1.35–1.15 (m, 11H), 0.95–0.82 (m, 2H); ¹³C-NMR: δ (ppm) 173.0, 171.1, 148.1, 147.6, 146.1, 127.0, 107.0, 60.4, 60.2, 49.3, 48.2, 39.6, 33.7, 33.0, 32.8, 30.3, 30.0, 29.0, 25.3, 24.8, 24.7, 24.5, 22.2, 14.1; IR (thin film): 2924, 2840, 2361, 1727, 1644, 1660, 1517, 1448, 1374, 1277, 1260, 1163, 1098, 1064, 1028 cm⁻¹; HRMS: Calcd. for C₂₄H₄₇N₅O₁₅: 415.2835, Found: 415.2837.

Ethyl 3-((1-(tert-butylcarbamoyl)-3-methylbutyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)propanoate (2c). Pale brown liquid, (85 mg, 27%), ¹H-NMR: δ (ppm) 8.23 (s, 1H), 8.14 (d, 1H, J = 5.8 Hz), 6.55 (d, 1H, J = 5.8 Hz), 5.85 (br s, 1H), 4.10 (q, 2H, J = 7.1 Hz), 3.82 (t, 1H, J = 6.5 Hz), 3.74–3.62 (m, 2H), 3.00–2.87 (m, 1H), 2.30 (t, 2H, J = 7.0 Hz), 2.26–2.17 (m, 1H), 2.06–1.96 (m, 1H), 1.94–1.83 (m, 1H), 1.65–1.55 (m, 2H), 1.32 (s, 9H), 1.31–1.18 (m, 9H); ¹³C-NMR: δ (ppm) 173.0, 171.1, 156.2, 148.0, 146.7, 127.4, 107.0, 60.9, 60.4, 51.2, 49.4, 39.6, 33.8, 33.3, 30.3, 28.5, 24.6, 22.2,
Molecules 2011, 16 9269

14.2; IR (thin film): 2960, 2933, 2361, 1727, 1666, 1596, 1543, 1505, 1448, 1365, 1277, 1255, 1220, 1163 cm⁻¹; HRMS: Calcd. for C₂₂H₃₅N₃O₃: 389.2678, Found: 389.2679.

**Ethyl 3-(7-(1-(cyclohexylcarbamoyl)propyl)-6,7-dihydro-4-methyl-2-phenyl-5H-pyrrolo[2,3-d]-pyrimidin-5-yl)propanoate** (2d). Pale yellow liquid, (265 mg, 55%), ¹H-NMR: δ (ppm) 8.40–8.30 (m, 2H), 7.54–7.38 (m, 3H), 6.52 (br s, 1H), 4.63–4.45 (m, 1H), 4.09 (q, 2H, J = 7.0 Hz), 3.80–3.60 (m, 2H), 3.50–3.25 (m, 2H), 2.40 (s, 3H), 2.37–2.24 (m, 2H), 2.18–1.96 (m, 2H), 1.94–1.70 (m, 4H), 1.63–1.38 (m, 3H), 1.34–1.14 (m, 6H), 1.05–0.80 (m, 5H); IR (thin film): 2960, 2933, 2361, 1727, 1666, 1596, 1543, 1505, 1448, 1365, 1277, 1255, 1220, 1163 cm⁻¹; HRMS: Calcd. for C₂₂H₃₅N₃O₃: 389.2678, Found: 389.2679.

**N-Cyclohexyl-2-(5,6-dihydro-4-methyl-5-(3-oxobutyl)-2-phenylpyrrolo[2,3-d]pyrimidin-7-yl)butan-amide** (2e). Yellow liquid, (75 mg, 44%), ¹H-NMR: δ (ppm) 8.40–8.25 (m, 2H), 7.55–7.35 (m, 3H), 6.50 (d, 1H, J = 8.0 Hz), 4.50 (t, 1H, J = 6.6 Hz), 3.78–3.58 (m, 2H), 3.45–3.25 (m, 2H), 2.47 (t, 2H, J = 7.5 Hz), 2.40 (s, 3H), 2.16–2.00 (m, 5H), 1.90–1.85 (m, 4H), 1.60–1.34 (m, 4H), 1.30–1.14 (m, 2H), 1.10–0.85 (m, 5H); ¹³C-NMR: δ (ppm) 207.9, 169.3, 166.5, 162.9, 157.8, 138.1, 130.0, 128.2, 127.7, 117.7, 58.2, 51.2, 47.8, 39.4, 35.1, 32.7, 30.0, 27.4, 25.3, 24.4, 24.2, 21.0, 20.9, 14.2, 10.8; IR (thin film): 2929, 2853, 1710, 1656, 1603, 1564, 1508, 1454, 1377, 1317, 1247, 1159, 1064 cm⁻¹, HRMS: Calcd. for C₂₇H₃₆N₄O₂: 448.2838, Found: 448.2836.

**Ethyl 3-(7-(N-p-tolylmethan-carbamoylmethyl)-6,7-dihydro-4-methyl-2-phenyl-5H-pyrrolo[2,3-d]-pyrimidin-5-yl)propanoate** (2f). Pale yellow liquid, (125 mg, 27%), ¹H-NMR: δ (ppm) 8.28 (d, 2H, J = 7.6 Hz), 7.45–7.34 (m, 3H), 7.10 (d, 2H, J = 7.6 Hz), 7.00 (d, 2H, J = 7.6 Hz), 6.95 (br s, 1H), 4.50–4.25 (m, 3H), 4.08–3.95 (m, 3H), 3.79–3.65 (m, 1H), 3.45–3.35 (m, 2H), 2.40 (s, 3H), 2.33–2.20 (m, 5H), 2.10–2.00 (m, 1H), 1.96–1.85 (m, 1H), 1.20 (t, 3H, J = 7.0 Hz); ¹³C-NMR: δ (ppm) 173.0, 169.0, 167.0, 163.6, 158.5, 138.0, 137.1, 135.0, 130.1, 129.4, 128.3, 127.6, 117.4, 60.8, 55.8, 49.5, 43.2, 35.8, 30.8, 28.7, 21.1, 21.0, 14.2; IR (thin film): 2924, 2356, 1731, 1662, 1605, 1583, 1570, 1518, 1448, 1377, 1325, 1260, 1172, 1024 cm⁻¹, HRMS: Calcd. for C₂₈H₃₈N₄O₃: 472.2474, Found: 472.2473.

**Ethyl 3-(7-(1-(1-(cyclohexylcarbamoyl)propyl)-2,3-dihydro-5-nitro-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate** (2g). Pale brown liquid, (297 mg, 48%), ¹H-NMR: δ (ppm) 8.86 (s, 1H), 7.92 (s, 1H), 6.04 (br s, 1H), 4.05 (t, 1H, J = 7.5 Hz), 4.15 (q, 2H, J = 7.2 Hz), 4.00–3.83 (m, 1H), 3.79–3.62 (m, 1H), 3.55–3.30 (m, 2H), 2.44–2.30 (m, 2H), 2.20–1.98 (m, 2H), 1.94–1.76 (m, 3H), 1.74–1.64 (m, 3H), 1.62–1.50 (m, 2H), 1.34–1.25 (m, 6H), 1.20–1.10 (m, 1H), 0.95 (t, 3H, J = 7.2 Hz); ¹³C-NMR: δ (ppm) 172.5, 168.1, 164.6, 146.7, 136.6, 126.7, 125.7, 60.8, 58.5, 51.9, 48.2, 36.2, 33.0, 31.0, 30.9, 29.5, 25.4, 24.6, 24.5, 21.4, 14.3, 10.7; IR (thin film): 2933, 2850, 2356, 1731, 1657, 1609, 1574, 1517, 1496, 1443, 1377, 1291, 1186, 1090, 1024 cm⁻¹, HRMS: Calcd. for C₂₂H₅₂N₄O₅: 432.2373, Found: 432.2386.
N-Cyclohexyl-2-(5,6-dihydro-2,4-dimethyl-5-(3-oxo-3-phenylpropyl)pyrrolo[2,3-d]pyrimidin-7-yl)-butanamide (2h). Pale brown liquid, (150 mg, 34%), $^1$H-NMR: δ (ppm) 7.90 (d, 2H, $J = 7.8$ Hz), 7.58–7.54 (m, 1H), 7.48 (d, 1H, $J = 7.8$ Hz), 4.41 (t, 1H, $J = 7.7$ Hz), 3.80–3.65 (m, 2H), 3.46–3.30 (m, 2H), 3.08–2.83 (m, 1H), 2.45 (s, 3H), 2.30 (s, 3H), 2.26–2.14 (m, 1H), 2.08–1.96 (m, 1H), 1.94–1.40 (m, 7H), 1.30–0.98 (m, 5H), 0.90 (t, 3H, $J = 7.3$ Hz); $^{13}$C-NMR: δ (ppm) 199.3, 169.2, 166.1, 157.2, 136.6, 133.2, 128.6, 127.9, 116.8, 58.0, 50.7, 47.9, 35.2, 34.1, 33.0, 32.8, 28.2, 25.4, 24.4, 21.1, 20.6, 10.8; IR (thin film): 2929, 2853, 1671, 1611, 1568, 1515, 1446, 1404, 1358, 1317, 1270, 1259, 1083 cm$^{-1}$, HRMS: Calcd. for C$_{27}$H$_{36}$N$_4$O$_2$: 448.2838, Found: 448.2843.

Ethyl 3-(7-(1-(4-chlorobenzylcarbamoyl)-2-methylpropyl)-6,7-dihydro-2,4-dimethyl-5H-pyrrolo[2,3-d]pyrimidin-5-yl)propanoate (2i). Pale yellow liquid, (203 mg, 43%), $^1$H-NMR: δ (ppm) 7.22 (d, 2H, $J = 8.0$ Hz), 7.07 (d, 2H, $J = 8.0$ Hz), 4.39 (dd, 2H, $J = 6.0, 14.7$ Hz), 4.12 (q, 2H, $J = 7.0$ Hz), 3.73 (t, 1H, $J = 7.0$ Hz), 3.40–3.20 (m, 2H), 2.51–2.38 (m, 1H), 2.35 (s, 3H), 2.28 (s, 3H), 2.23 (t, 2H, $J = 7.5$ Hz), 2.10–1.90 (m, 1H), 1.80–1.65 (m, 1H), 1.25 (t, 3H, $J = 7.0$ Hz), 1.00 (d, 3H, $J = 7.0$ Hz), 0.87 (d, 3H, $J = 7.0$ Hz); $^{13}$C-NMR: δ (ppm) 172.8, 169.6, 166.1, 165.9, 157.3, 136.7, 133.2, 128.9, 128.7, 116.6, 64.0, 60.6, 51.5, 42.6, 35.2, 30.6, 28.9, 26.4, 25.7, 20.6, 19.5, 19.1, 14.2; IR (thin film): 2964, 2924, 1731, 1671, 1609, 1570, 1531, 1469, 1403, 1273, 1177, 1094, 1011 cm$^{-1}$, HRMS: Calcd. for C$_{25}$H$_{33}$ClN$_4$O$_3$: 472.2241, Found: 472.2244.

4. Conclusions

The reported two-step cascade constitutes a concise entry into pyrrolidino- pyridines and pyrimidines. Compared with previous results obtained on xanthate cascades performed on N-allylaminopyridine and pyrimidines, these new couplings significantly widen the scope of these reactions. The modest efficiency of the whole process is counter-balanced by the simple experimental procedure and the straightforward access to important biologically relevant scaffolds [40-43]. This work is a new example of the potential of radical chemistry in Ugi post-condensations.

Acknowledgements

P. P. thanks the ANR-CP2D Program (ANR MUSE) for a fellowship.

References and Notes


39. The structure of the major diastereomers could not be determined with usual NMR techniques.


*Sample Availability:* Not available.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).